NNVC NanoViricides, Inc. Stock Quote

NNVC [AMEX]

Index	-	P/E	-	EPS (ttm)	-0.73	Insider Own	5.16%	Shs Outstand	11.54M	Perf Week	-21.47%
Market Cap	30.61M	Forward P/E	-	EPS next Y	-0.91	Insider Trans	0.00%	Shs Float	10.96M	Perf Month	43.30%
Income	-8.40M	PEG	-	EPS next Q	-0.23	Inst Own	10.00%	Short Float	1.56%	Perf Quarter	148.21%
Sales	-	P/S	-	EPS this Y	66.20%	Inst Trans	-0.54%	Short Ratio	0.28	Perf Half Y	16.81%
Book/sh	2.15	P/B	1.29	EPS next Y	-16.70%	ROA	-30.20%	Target Price	8.50	Perf Year	-29.62%
Cash/sh	1.42	P/C	1.96	EPS next 5Y	-	ROE	-30.70%	52W Range	1.04 - 7.86	Perf YTD	-25.27%
Dividend	-	P/FCF	-	EPS past 5Y	26.30%	ROI	-	52W High	-63.74%	Beta	0.97
Dividend %	-	Quick Ratio	41.20	Sales past 5Y	-	Gross Margin	-	52W Low	174.04%	ATR	0.36
Employees	17	Current Ratio	41.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	57.45	Volatility	13.39% 13.56%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	19.30%	Profit Margin	-	Rel Volume	0.25	Prev Close	2.78
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	609.03K	Price	2.85
Recom	2.00	SMA20	17.33%	SMA50	30.77%	SMA200	6.65%	Volume	61,060	Change	2.52%

Feb-11-15

Initiated

Midtown Partners

Strong Buy

$5.30

Aug-10-22 08:00AM	Monkeypox Is Popping Up In Places It Shouldnt But NanoViricides SaysIt May Have A Solution News Direct
Aug-09-22 06:45AM	NanoViricides Provides Additional Details on Its Rapid Monkeypox Drug Strategy ACCESSWIRE -9.71%
Aug-04-22 09:01AM	NanoViricides shares soar 41% after announcing plans to develop a monkeypox treatment MarketWatch +48.37%
06:45AM	NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox Virus ACCESSWIRE
May-17-22 06:45AM	NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2022 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Progressing Further for Clinical Trials Application ACCESSWIRE
May-16-22 12:22PM	NanoViricides Starts Drug Development Program For Recent Cases Of Unexplained Pediatric Hepatitis Benzinga +12.19%
06:45AM	NanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric Hepatitis ACCESSWIRE
Apr-25-22 06:45AM	NanoViricides Provides Update On NV-CoV-2 Coronavirus Drug Candidate Program ACCESSWIRE
Feb-15-22 06:45AM	NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready ACCESSWIRE
Nov-16-21 06:45AM	NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical Trials ACCESSWIRE
Nov-15-21 07:31AM	EXCLUSIVE: NanoViricides Completes Oral Gummies, Lung Inhalation Formulations For COVID-19 Treatment Benzinga
06:45AM	NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2 ACCESSWIRE
06:18AM	EXCLUSIVE: NanoViricides Develops Chewable Pills, Lung Inhalation Formulations For COVID-19 Candidate Benzinga
Oct-13-21 06:45AM	NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage ACCESSWIRE +14.69%
Oct-11-21 08:25AM	NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity Benzinga
06:45AM	NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity ACCESSWIRE
Oct-05-21 08:31AM	NanoViricides Leaps Forward in its Quest to Defeat COVID-19 Benzinga +5.64%
06:45AM	NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap Conference PR Newswire
Sep-28-21 09:28AM	Company News for Sep 28, 2021 Zacks
Sep-27-21 07:02AM	20 Stocks Moving in Monday's Pre-Market Session Benzinga
06:45AM	NanoViricides, Inc. Invites You to Join Us at the Benzinga Healthcare Small Cap Conference for Update on Pan-Coronavirus COVID-19 Drug Development Program Newsfile
Sep-22-21 06:45AM	Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug PR Newswire -7.11%
06:45AM	Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug CNW Group
Sep-21-21 02:18PM	Nanoviricides Stock Surges, Nears The End Of A Pennant Pattern Benzinga +63.32%
Sep-14-21 12:04PM	36 Stocks Moving In Tuesday's Mid-Day Session Benzinga +18.67%
07:32AM	NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development Benzinga
06:45AM	NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development PR Newswire
Jun-28-21 08:28AM	Nanomedicine Company Makes "Nanomachines" that Attack Viruses Benzinga
Jun-22-21 12:49PM	NanoViricides Review: What you Need to Know About the Company Benzinga +7.89%
May-17-21 06:45AM	NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards IND ACCESSWIRE
Mar-09-21 08:08AM	The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu's Positive COVID-19 Data Benzinga
05:45AM	NanoViricides, Inc. Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective in Pre-clinical Animal Studies in Support of FDA Pre-IND Application ACCESSWIRE
Mar-02-21 08:01AM	The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data Benzinga +57.58%
06:15AM	NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application ACCESSWIRE
04:43AM	NanoViricides Reports 'Strong Effectiveness' for COVID Drugs TheStreet.com
Feb-18-21 04:59AM	We're Hopeful That NanoViricides (NYSEMKT:NNVC) Will Use Its Cash Wisely Simply Wall St. -7.61%
Feb-17-21 06:15AM	NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2020 - Has Sufficient Cash, Coronavirus Drug Candidate Safe in GLP Safety Toxicology Moving Towards IND ACCESSWIRE
Feb-08-21 07:40AM	NanoViricides' Broad-Spectrum Antiviral Drug Candidate Shows Encouraging Action In Preclinical Studies For COVID-19 Benzinga +13.80%
06:15AM	NanoViricidess Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP and non-GLP Animal Safety Studies ACCESSWIRE
Jan-27-21 06:15AM	Broad-Spectrum Direct Antiviral Nanomedicine Should Remain Effective Against COVID-19 Virus Variants, Says NanoViricides, Inc.s President, Dr. Anil Diwan ACCESSWIRE
Nov-19-20 06:20AM	NanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA ACCESSWIRE
Nov-18-20 11:49AM	Small Caps Daily Features NanoViricides' Rapid Advancement to Clinical Trials for its COVID-19 Therapy Newsfile
Nov-17-20 06:20AM	NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2020 - Has Sufficient Cash, Coronavirus Drug Development Progress ACCESSWIRE
Nov-11-20 10:55AM	NanoViricides: One Step at a Time GuruFocus.com
06:20AM	NanoViricides Has Engaged Calvert Labs for Safety Pharmacology Studies of Its Drug for the Treatment of COVID-19 ACCESSWIRE
Oct-15-20 06:15AM	NanoViricides, Inc. Has Filed its Annual Report: Strengthened Financial Position and Rapidly Developing Novel Coronavirus Drug Program ACCESSWIRE
Sep-18-20 05:35PM	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NanoViricides, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm Business Wire
Sep-16-20 06:15AM	NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19 ACCESSWIRE
Sep-08-20 09:10AM	NanoViricides, Inc. Investors Who Purchased NNVC Securities Between January 23, 2020 and July 13, 2020 And Suffered Significant Losses Encouraged To Contact Kehoe Law Firm, P.C. PR Newswire -8.62%
Sep-04-20 06:50AM	NanoViricides is Developing Drugs Against SARS-CoV-2 with an Integrated Approach to Combat COVID-19, as Reported at The LD 500 Virtual Conference ACCESSWIRE -11.91%
Sep-02-20 06:15AM	NanoViricides to Present COVID-19 Drug Update at The LD 500 Virtual Conference ACCESSWIRE +42.35%
Aug-31-20 05:00PM	(LD Micro) 360 Companies Set to Present this Week ACCESSWIRE
08:40AM	Small Caps Daily Features NanoViricides' Progress on Developing a Therapy To Help Kids Return To School Safely Newsfile
Aug-06-20 01:43PM	LD Micro: Announces Preliminary List of Presenters for the LD-500 ACCESSWIRE
Jul-23-20 11:48AM	NanoViricides, Inc. Raises $11.5 Million Through Public Offering After Positive Test Results For COVID-19 Drug Newsfile
Jul-21-20 06:15AM	NanoViricides to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit Today, July 21, 2020 ACCESSWIRE
Jul-20-20 06:10PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds NanoViricides (NNVC) Investors of Proprietary Investigation into Possible Securities Law Violations, Encourages Investors and Persons Who May be Able to Assist Investigation to Contact Firm GlobeNewswire
Jul-16-20 03:16PM	Glancy Prongay & Murray LLP, a National Class Action Law Firm, Announces Investigation of NanoViricides, Inc. (NNVC) on Behalf of Investors Business Wire
10:52AM	NanoViricides, Inc. Investors Who Purchased NNVC Securities After January 2020 And Suffered Losses Greater Than $50,000 Encouraged To Contact Kehoe Law Firm, P.C. GlobeNewswire
Jul-13-20 06:30AM	NanoViricides Closes On $11.5 Million Underwritten Public Offering of Common Stock ACCESSWIRE
Jul-09-20 06:15AM	NanoViricides Prices $10.0 Million Underwritten Public Offering of Common Stock ACCESSWIRE -10.56%
Jul-08-20 05:55PM	Nanoviricides Commences Underwritten Public Offering of Common Stock ACCESSWIRE +25.87%
05:50PM	Covid-19 Research Update: The Stars and the Question Marks GuruFocus.com
06:15AM	Safety and Tolerability of Anti-Coronavirus Drug Candidates Observed in an Animal Model Further Advances NanoViricides SARS-CoV-2 Therapeutics Program ACCESSWIRE
Jun-30-20 06:15AM	NanoViricides Announces Addition to Russell Microcap(R) Index ACCESSWIRE
Jun-25-20 11:05AM	NanoViricides: Sufficient Funding for Covid-19 Research GuruFocus.com +20.11%
Jun-23-20 06:15AM	NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2020 - Has Sufficient Cash, Progress on New Coronavirus Drug Program and the Lead HerpeCide(TM) Drug Candidate IND Application ACCESSWIRE +11.42%
Jun-09-20 07:46AM	The Daily Biotech Pulse: Soleno Flunks Late-Stage Study, Sanofi Strikes Breast Cancer Partnership, NanoViricides Shortlists Coronavirus Treatment Candidates Benzinga +9.16%
06:15AM	NanoViricides Signs Memorandum of Understanding for Human Coronavirus Drug Development License ACCESSWIRE
May-26-20 06:15AM	NanoViricides Announces Completion of $10.2 Million Registered Direct Offering - Funds to Accelerate COVID-19 Drug Program and HerpeCide Program ACCESSWIRE
May-21-20 08:30AM	NanoViricides Announces Pricing of $10.2 Million Registered Direct Offering ACCESSWIRE -15.73%
May-20-20 06:15AM	Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus ACCESSWIRE -5.80%
May-18-20 06:15AM	Honorable Ex-Congressman Todd Rokita Joins the Board of Directors of NanoViricides, Inc. ACCESSWIRE +5.30%
May-13-20 10:12AM	Company News for May 13, 2020 Zacks +15.57%
May-12-20 12:57PM	NanoViricides: New Covid-19 Drug Candidates Could Boost Performance GuruFocus.com +28.27%
06:15AM	NanoViricides Develops Highly Effective Broad-Spectrum Drug Candidates Against Coronaviruses ACCESSWIRE
May-04-20 06:15AM	NanoViricides Signs Confidential Disclosure Agreement with International Pharmaceutical Company to Explore Collaborating on its COVID-19 Program ACCESSWIRE +14.71%
Apr-29-20 06:15AM	NanoViricides Presentation on COVID-19 and Shingles Drug Development Update at the Planet MicroCap Showcase Virtual Investor Conference 2020 is Now Available ACCESSWIRE -6.29%
Apr-21-20 02:00PM	NanoViricides to Present COVID-19 and Shingles Drug Development Update at the Planet MicroCap Showcase Virtual Investor Conference 2020 on April 22nd ACCESSWIRE +33.62%
Apr-13-20 06:15AM	NanoViricides President Dr. Anil Diwan was Interviewed by Proactive Investors About the Companys Antiviral Drug Development Against SARS-CoV-2 to Treat COVID-19 ACCESSWIRE
Apr-07-20 02:31PM	Does NanoViricides, Inc. (NYSEMKT:NNVC) Have A High Beta? Simply Wall St.
11:49AM	NanoViricides: The Visit From Senator Blumenthal Is a Positive Development GuruFocus.com
Apr-06-20 06:15AM	U.S. Senator Richard Blumenthal Visited NanoViricides Inc. for Update on Coronavirus (COVID-19) Drug Development Efforts ACCESSWIRE
Mar-31-20 07:30AM	NanoViricides, Inc. Progress on COVID-19 Drug Encouraging Newsfile
Mar-16-20 06:15AM	Coronavirus Drug Development Update from NanoViricides, Inc. ACCESSWIRE +6.12%
Mar-14-20 10:18AM	Inovio stock rallies after company gets Gates Foundation grant to test device for coronavirus vaccine MarketWatch
Mar-13-20 05:42PM	The Coronavirus Pandemic Has Revealed Some Micro-Cap Opportunities GuruFocus.com -9.74%
Mar-09-20 02:44PM	Is Inovio Pharmaceuticals Stock the Cure for Your Portfolio? InvestorPlace -17.96%
Mar-05-20 04:11PM	NanoViricides, Inc. Reports Discovery of Broad-Spectrum Virus-Binding Ligands; Expected to Counter COVID-19 Newsfile
Feb-28-20 04:57PM	Dow, S&P 500 fall for 7th straight day; stocks suffer biggest weekly fall since 2008 MarketWatch -7.95%
Feb-25-20 03:25PM	18 Medical Stocks To Watch Amid The Coronavirus Outbreak Benzinga -13.76%
Feb-24-20 08:39AM	NanoViricides stock soars amid fears of global spread of COVID-19 MarketWatch +38.37%
08:04AM	Benzinga Pro's Top 5 Stocks To Watch For Mon., Feb. 24, 2020: NNVC, WFC, SPCE, LL, CETX Benzinga
06:15AM	NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2019 - Has Sufficient Cash, HerpeCide(TM) Drug Candidate IND Application Development in Progress ACCESSWIRE
Feb-18-20 01:01PM	The Wuhan Virus and Research-Focused Biotech Companies GuruFocus.com
Feb-12-20 06:15AM	Dr. Mak Jawadekar Joins the Board of Directors of NanoViricides, Inc. ACCESSWIRE -7.03%
Feb-10-20 07:30AM	Nanoviricides President Dr. Diwan Was Interviewed by The Varney Show on Fox Business News ACCESSWIRE +17.41%
Feb-06-20 05:50PM	Can Biotech ETFs Continue to Soar in 2020? Zacks -7.91%
Feb-04-20 07:30AM	Nanoviricides President Dr. Diwan Was Interviewed By The Kennedy Show On Fox Business News ACCESSWIRE -6.38%
Feb-03-20 02:17PM	Coronavirus update: 361 have died, there are now 11 cases in the U.S. and the case count has doubled SARS MarketWatch -35.44%

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience